Risk Factors for Small Adult Height in Childhood Cancer Survivors.
Adolescent
Age Factors
Antineoplastic Agents, Alkylating
/ adverse effects
Body Height
Busulfan
/ adverse effects
Cancer Survivors
Child
Child, Preschool
Female
France
/ epidemiology
Growth Disorders
/ diagnosis
Hormone Replacement Therapy
Human Growth Hormone
/ blood
Humans
Lomustine
/ adverse effects
Male
Neoplasms
/ epidemiology
Puberty
Radiation Injuries
/ diagnosis
Radiotherapy
/ adverse effects
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
pubmed:
21
3
2020
medline:
2
2
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
Between 10% and 20% of childhood cancer survivors (CCS) experience impaired growth, leading to small adult height (SAH). Our study aimed to quantify risk factors for SAH or growth hormone deficiency among CCS. The French CCS Study holds data on 7,670 cancer survivors treated before 2001. We analyzed self-administered questionnaire data from 2,965 CCS with clinical, chemo/radiotherapy data from medical records. SAH was defined as an adult height ≤ 2 standard deviation scores of control values obtained from a French population health study. After exclusion of 189 CCS treated with growth hormone, 9.2% (254 of 2,776) had a SAH. Being young at the time of cancer treatment (relative risk [RR], 0.91 [95% CI, 0.88 to 0.95] by year of age), small height at diagnosis (≤ 2 standard deviation scores; RR, 6.74 [95% CI, 4.61 to 9.86]), pituitary irradiation (5-20 Gy: RR, 4.24 [95% CI, 1.98 to 9.06]; 20-40 Gy: RR, 10.16 [95% CI, 5.18 to 19.94]; and ≥ 40 Gy: RR, 19.48 [95% CI, 8.73 to 43.48]), having received busulfan (RR, 4.53 [95% CI, 2.10 to 9.77]), or > 300 mg/m CCS are at a high risk of SAH. CCS treated with radiotherapy, busulfan, or lomustine should be closely monitored for growth, puberty onset, and potential pituitary deficiency.
Identifiants
pubmed: 32196392
doi: 10.1200/JCO.19.02361
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Human Growth Hormone
12629-01-5
Lomustine
7BRF0Z81KG
Busulfan
G1LN9045DK
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM